In a letter to healthcare providers, the US FDA summarized a recent evaluation of a postapproval study of the Abiomed Impella RP system. In clinical trials, 73% of patients survived 30 days after device explant, hospital discharge, or to definitive intervention. In the postapproval study, just over 17% of patients met this goal.
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Heart Failure - Nonischemic
Postmarket Experience With HeartMate 3 Left Ventricular Assist Device: 30-Day Outcomes From the ELEVATE Registry
January 30, 2019
Garbade and colleagues compared outcomes reported during the European Conformity (CE) Mark clinical trial of the HeartMate 3 left ventricular assist device (LVAD) to outcomes for patients treated since the device came to market.
Right Ventricular Pulmonary Coupling as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction
January 18, 2019
A good attempt to shed some light into the somewhat challenging concept of heart failure with preserved ejection fraction, on the occasion of a small randomized controlled trial on albuterol.
Six-Month Outcomes After Treatment of Advanced Heart Failure With a Full Magnetically Levitated Continuous Flow Left Ventricular Assist Device: Report From the ELEVATE Registry
October 23, 2018
A post-market study (ELEVATE registry) of the fully magnetically levitated continuous flow HeartMate III left ventricular assist device (LVAD) found no pump thrombosis in 463 patients in Europe and Kazakhstan.
May 15, 2018
A sober editorial on a murine model of induced cardiac failure, which highlights the challenges of translating animal omics to humans
March 12, 2018
An interesting two-year report from the MOMENTUM 3 randomized controlled trial comparison of HeartMate 3 and II, the analysis performed by Abbott. Although stroke and reoperation were clearly lower with the latest technology, reflected in the lower LDH measurements, there was bafflingly no improvement in survival.
March 1, 2018
A 16-year retrospective analysis of cardiac transplantation outcomes, recommending cold ischemic times of less than two hours for older donors.
Selective Implantation of Durable Left Ventricular Assist Devices as Primary Therapy for Refractory Cardiogenic Shock
February 28, 2018
A retrospective Mount Sinai small series on selective emergent implantation of long-term ventricular assist devices in cardiogenic shock. It challenges the traditional concept of short-term stabilisation with ECMO or short-term support, and is likely to generate criticism and discussions.
February 2, 2018
An editorial from an influential source discussing the recent robust results of the CASTLE-AF RCT trial. It is likely that interventions for atrial fibrillation will be boosted by these results, in terms of insurance, industry, and clinical guideline support.
June 13, 2017
A succinct review of cardiac amyloidosis, particularly relevant to transplant surgeons that are expected to see more patients with the condition